Find disease awareness content and relevant supporting materials
Symplicity Spyral RND system demonstrates significant blood pressure reduction through three years.
Medtronic plc announced long-term data from the first 80 patients in the SPYRAL HTN-ON MED trial, which were presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22) late-breaking featured clinical research sessions.
U.S commercial launch of the UroLift 2 system and UroLift ATC advanced tissue control system to manage benign prostatic hyperplasia.- Teleflex Inc.
Teleflex Incorporated announced the full U.S. commercial launch of its UroLift 2 System and UroLift ATC System, and that it will update the urology community through multiple in-booth presentations at the 2022 American Urological Association (AUA) annual meeting. The conference will take place in-person from May 13-16 in New Orleans.
Zealand Pharma agrees to sell V-Go insulin delivery device to MannKind Corporation.
Zealand Pharma announced it has entered into an asset purchase agreement with MannKind Corporation ( to sell the V-Go insulin delivery device for $10 million and additional sales-based milestones).
U.S. Emergency Use Authorization for booster dose of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age.
Pfizer Inc. and BioNTech SE announced the FDA expanded emergency use authorization (EUA) to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age.
CHMP recommends Olumiant for the treatment of adults with severe alopecia areata.-Eli Lilly.
Eli Lilly and Company and Incyte announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA).
CHMP recommends Cevenfacta to control bleeding episodes in patients with congenital haemophilia.
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cevenfacta, intended for the treatment of bleeding episodes.
Fifty percent of patients with ulcerative colitis treated with mirikizumab achieved clinical remission at one year in Phase III LUCENT-2 study.
In Eli Lilly and Company's pivotal, Phase III LUCENT-2 study, patients with ulcerative colitis (UC) who responded to mirikizumab at 12 weeks achieved and maintained statistically superior and clinically meaningful improvements at one year compared to placebo across the primary endpoint of clinical remission and all key secondary endpoints, including bowel urgency severity, using a novel, patient-reported outcome measure.
Rinvoq achieved clinical remission and endoscopic response at one year in phase III maintenance study in patients with Crohn's disease
AbbVie announced positive topline results from U-ENDURE, its Phase III maintenance study evaluating upadacitinib in adult patients with moderate to severe Crohn's disease who had an inadequate response or were intolerant to a conventional or biologic therapy.
NVX-CoV2373 vaccine is filed for Emergency Use Authorization to prevent COVID 19 in Taiwan. Novavax
Novavax announced the submission of a request for emergency use authorization to Taiwan’s Food and Drug Administration for its COVID-19 vaccine, NVX-CoV2373, for active immunization against SARS-CoV-2 in individuals aged 18 and over.
NMPA (China) approves Verkazia to treat vernal keratoconjunctivitis (VKC) in children and adolescents.- Santen
Santen Pharmaceutical has obtained Chinese regulatory approval for Verkazia (ciclosporin) eye drops for the treatment of severe vernal keratoconjunctivitis (VKC) in children and adolescents aged four years and older.